Lantheus (LNTH) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Key product and pipeline highlights

• PYLARIFY is on track to become the first blockbuster diagnostic, significantly impacting patient care in urology.

• Neurology assets include best-in-class beta amyloid and tau agents for diagnosis, monitoring, and therapeutic selection.

• PNT2002 for prostate cancer is nearing a 75% OS readout; PNT2003 for neuroendocrine tumors targets a spring 2026 launch.

• Early-stage pipeline includes GRPR-targeted RM2, LRRC15, and Trop-2, expanding into new tumor types and pediatric indications.

• Strategic focus is shifting to earlier-stage assets, allowing more control over development and combination strategies.

Strategic direction and leadership

• Recent CEO transition brings continuity and renewed focus on pipeline expansion and R&D.

• Strong commercial performance is funding acquisitions and development of new assets.

• Emphasis on acquiring scientifically sound, commercially viable, and reasonably priced assets.

• Diagnostics remain a core focus, as Big Pharma prioritizes therapeutics, leaving diagnostic innovation opportunities.

Isotope strategy and supply chain

• Diagnostic agents primarily use F-18, supported by a robust U.S. PET manufacturing network for broad coverage.

• F-18 offers logistical and imaging advantages over gallium-68, including longer half-life and crisper images.

• Copper-64 is being explored for FAPI agents due to its long half-life and central manufacturing potential.

• Isotope selection is tailored to each agent; gallium-68, lutetium-177, and others are used as appropriate.

• Non-carrier-added lutetium-177 is preferred for cleaner waste management and easier handling by providers.